Atopic Dermatitis Clinical Trials in San Antonio, Texas

7 studies are recruiting for atopic dermatitis in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

   This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Investigational Site, San Antonio, Texas

   Locations

   71 in total

   Run by

   Apogee Therapeutics, Inc.

   See if you can join NCT07003425 on ClinicalTrials.gov

2. A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

   This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrociti…

   Stage

   Phase 3

   Ages

   2 to 11

   Site

   Texas Dermatology and Laser Specialists, San Antonio, Texas

   Locations

   41 in total

   Run by

   Pfizer

   See if you can join NCT06807281 on ClinicalTrials.gov

3. A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

   This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Progressive Clinical Research, PA, San Antonio, Texas

   Locations

   85 in total

   Run by

   Apollo Therapeutics Ltd

   See if you can join NCT07599813 on ClinicalTrials.gov

4. Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

   This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

   Stage

   Phase 2

   Ages

   18 to 100

   Site

   Novartis Investigative Site, San Antonio, Texas

   Locations

   105 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06947993 on ClinicalTrials.gov

5. A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

   Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupil…

   Stage

   Phase 3

   Ages

   2 to 11

   Site

   Texas Dermatology and Laser Specialists /ID# 267249, San Antonio, Texas

   Locations

   150 in total

   Run by

   AbbVie

   See if you can join NCT06461897 on ClinicalTrials.gov

6. A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

   This double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of ENV-294 in adults with moderate-to-severe atopic dermatitis (AD). The study will compare three dose levels of ENV-294 with placebo administered for 12 weeks. Participants will undergo screening, receive s…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Enveda Investigative Site, San Antonio, Texas

   Locations

   9 in total

   Run by

   Enveda Therapeutics

   See if you can join NCT07643766 on ClinicalTrials.gov

7. A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

   The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   DCT-Stone Oak, LLC dba Discovery Clinical Trials, San Antonio, Texas

   Locations

   98 in total

   Run by

   Pfizer

   See if you can join NCT05995964 on ClinicalTrials.gov